Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Penicillin-binding protein 2 (PBP2) is an essential enzyme in the bacterium Cutibacterium acnes (formerly Propionibacterium acnes) that is vital for maintaining bacterial cell wall integrity. It functions as a transpeptidase, facilitating the cross-linking of peptidoglycan polymers, which allows the bacterium to survive environmental osmotic pressure [1, 2]. PBP2 is a member of the high-molecular-weight PBP family and serves as a critical target for beta-lactam antibiotics [3]. These drugs, including penicillins and cephalosporins, mimic the D-alanyl-D-alanine substrate and bind covalently to the enzyme's active site, permanently disabling its function [3, 4]. The resulting failure in cell wall synthesis triggers bacterial autolysis and cell death [3]. While C. acnes is a ubiquitous skin commensal, its overproliferation and biofilm formation are central to the pathogenesis of acne vulgaris [5]. Beyond dermatology, the organism is increasingly recognized as a cause of deep-tissue infections, such as prosthetic joint infections and endocarditis, where PBP2 remains a therapeutic focus [5, 6]. Therapeutic challenges include the rising prevalence of antibiotic-resistant C. acnes strains, which may involve structural modifications to PBPs that reduce drug affinity [4, 6]. Understanding the structural biology of PBP2 is therefore essential for developing next-generation antibiotics to combat resistant acne-causing bacteria. Sources: [1] UniProt Consortium. UniProtKB - Q6A7G1 (PBP2_CUTAC). https://www.uniprot.org/uniprotkb/Q6A7G1/entry [2] Scholz, C. F., & Kilian, M. (2016). Int J Syst Evol Microbiol. https://pubmed.ncbi.nlm.nih.gov/27424062/ [3] Bush, K., & Bradford, P. A. (2016). Cold Spring Harb Perspect Med. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971038/ [4] Dréno, B., et al. (2018). JEADV. https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.15043 [5] Achermann, Y., et al. (2014). Clin Microbiol Rev. https://pubmed.ncbi.nlm.nih.gov/25278577/ [6] McDowell, A., et al. (2013). J Clin Microbiol. https://pubmed.ncbi.nlm.nih.gov/22162554/
Covalent inhibition of the transpeptidase domain, preventing peptidoglycan cross-linking and leading to bacterial cell wall lysis.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Penicillin-binding protein 2 (Cutibacterium acnes) (PBP2).